| Bioactivity | Zoledronate (CGP 42446) disodium is a potent bisphosphonate that effectively inhibits osteoclastogenesis, reducing bone turnover and stabilizing the bone matrix. Zoledronate disodium has demonstrated notable effectiveness in managing Paget's disease of bone by suppressing metabolic activity and alleviating bone pain. Zoledronate disodium is being investigated in the ongoing ZiPP trial for its potential to prevent disease progression in patients with Paget's disease. Zoledronate disodium also exhibits diverse anti-tumor effects in osteosarcoma, further highlighting its multifunctional therapeutic applications. |
| CAS | 131654-46-1 |
| Formula | C5H8N2Na2O7P2 |
| Molar Mass | 316.05 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bisphosphonates in the management of Paget's disease |
Zoledronate disodium
CAS: 131654-46-1 F: C5H8N2Na2O7P2 W: 316.05
Zoledronate (CGP 42446) disodium is a potent bisphosphonate that effectively inhibits osteoclastogenesis, reducing bone
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.